Commonwealth Equity Services
MRKR icon

Commonwealth Equity Services’s Marker Therapeutics MRKR Stock Holding History

Commonwealth Equity Services’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,240
Closed -$3K – 3830
2022
Q4 		$3K Hold
1,240
– – ﹤0.01% 3687
2022
Q3 		$4K Hold
1,240
– – ﹤0.01% 3645
2022
Q2 		$4K Sell
1,240
-807
-39% -$2.68K ﹤0.01% 3651
2022
Q1 		$9K Hold
2,047
– – ﹤0.01% 3688
2021
Q4 		$19K Buy
2,047
+144
+8% +$1.91K ﹤0.01% 3608
2021
Q3 		$32K Buy
1,903
+120
+7% +$2.46K ﹤0.01% 3525
2021
Q2 		$49K Buy
+1,783
New +$46.9K ﹤0.01% 3461

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services's MRKR Position: Q1 2023 in Review

Commonwealth Equity Services sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 1,240 shares — an estimated $3K sold.

Commonwealth Equity Services first reported a position in MRKR in Q2 2021 and held it in 7 quarters. The position peaked at $49K in Q2 2021. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • Commonwealth Equity Services reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Commonwealth Equity Services sold 1,240 Marker Therapeutics shares in Q1 2023, an estimated $3K.
  • Commonwealth Equity Services first reported a position in Marker Therapeutics in Q2 2021 and held it in 7 quarters.
  • Commonwealth Equity Services's Marker Therapeutics position peaked at $49K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Commonwealth Equity Services's 13F filing for Q1 2023, filed 11 May 2023.